Clinical Trial Update: Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing a proposed ocrelizumab biosimilar CYB704 with Ocrevus in relapsing multiple sclerosis to assess PK, PD, efficacy, and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• CYB704 (ocelizumab biosimilar candidate) (ocrelizumab biosimilar)
• Ocrevus (ocrelizumab)

Snippet

Sponsor: Sandoz | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: RECRUITING